Works by Kisa, Renata M.

Results: 9
    1

    Deucravacitinib in moderate‐to‐severe plaque psoriasis: Pooled safety and tolerability over 52 weeks from two phase 3 trials (POETYK PSO‐1 and PSO‐2).

    Published in:
    Journal of the European Academy of Dermatology & Venereology, 2024, v. 38, n. 8, p. 1543, doi. 10.1111/jdv.19925
    By:
    • Strober, Bruce;
    • Blauvelt, Andrew;
    • Warren, Richard B.;
    • Papp, Kim A.;
    • Armstrong, April W.;
    • Gordon, Kenneth B.;
    • Morita, Akimichi;
    • Alexis, Andrew F.;
    • Lebwohl, Mark;
    • Foley, Peter;
    • Kisa, Renata M.;
    • Colston, Elizabeth;
    • Wang, Tao;
    • Banerjee, Subhashis;
    • Thaçi, Diamant
    Publication type:
    Article
    2
    3
    4

    Deucravacitinib in Moderate to Severe Psoriasis: Clinical and Quality-of-Life Outcomes in a Phase 2 Trial.

    Published in:
    Dermatology & Therapy, 2022, v. 12, n. 2, p. 495, doi. 10.1007/s13555-021-00649-y
    By:
    • Thaçi, Diamant;
    • Strober, Bruce;
    • Gordon, Kenneth B.;
    • Foley, Peter;
    • Gooderham, Melinda;
    • Morita, Akimichi;
    • Papp, Kim A.;
    • Puig, Lluís;
    • Menter, M. Alan;
    • Colombo, Matthew J.;
    • Elbez, Yedid;
    • Kisa, Renata M.;
    • Ye, June;
    • Napoli, Andrew A.;
    • Wei, Lan;
    • Banerjee, Subhashis;
    • Merola, Joseph F.;
    • Gottlieb, Alice B.
    Publication type:
    Article
    5

    Deucravacitinib onset of action and maintenance of response in phase 3 plaque psoriasis trials.

    Published in:
    Journal of Dermatological Treatment, 2024, v. 35, n. 1, p. 1, doi. 10.1080/09546634.2024.2371045
    By:
    • Korman, Neil J.;
    • Warren, Richard B.;
    • Bagel, Jerry;
    • Armstrong, April W.;
    • Gooderham, Melinda;
    • Strober, Bruce;
    • Thaçi, Diamant;
    • Morita, Akimichi;
    • Imafuku, Shinichi;
    • Foley, Peter;
    • Sofen, Howard;
    • Zheng, Min;
    • Hippeli, Lauren;
    • Kisa, Renata M.;
    • Banerjee, Subhashis;
    • Blauvelt, Andrew
    Publication type:
    Article
    6

    Deucravacitinib, an oral selective allosteric tyrosine kinase 2 inhibitor, in patients from China mainland, Taiwan and South Korea with moderate-to-severe plaque psoriasis: a phase III randomized clinical trial.

    Published in:
    British Journal of Dermatology, 2025, v. 192, n. 3, p. 402, doi. 10.1093/bjd/ljae406
    By:
    • Zhang, Jianzhong;
    • Ding, Yangfeng;
    • Wang, Ping;
    • Li, Linfeng;
    • Pan, Weili;
    • Lu, Yan;
    • Cheng, Hao;
    • Jiang, Xian;
    • Ho, Ji-Chen;
    • Guo, Shuping;
    • Liu, Leona;
    • Chatterjee, Arkendu;
    • Kisa, Renata M;
    • Banerjee, Subhashis
    Publication type:
    Article
    7
    8

    Safety and Efficacy of Deucravacitinib in Moderate to Severe Plaque Psoriasis for Up to 3 Years: An Open-Label Extension of Randomized Clinical Trials.

    Published in:
    JAMA Dermatology, 2025, v. 161, n. 1, p. 56, doi. 10.1001/jamadermatol.2024.4688
    By:
    • Armstrong, April W.;
    • Lebwohl, Mark;
    • Warren, Richard B.;
    • Sofen, Howard;
    • Imafuku, Shinichi;
    • Ohtsuki, Mamitaro;
    • Spelman, Lynda;
    • Passeron, Thierry;
    • Papp, Kim A.;
    • Kisa, Renata M.;
    • Vaile, John;
    • Berger, Victoria;
    • Vritzali, Eleni;
    • Hoyt, Kim;
    • Colombo, Matthew J.;
    • Scotto, Julie;
    • Banerjee, Subhashis;
    • Strober, Bruce;
    • Thaçi, Diamant;
    • Blauvelt, Andrew
    Publication type:
    Article
    9